Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078305 | 0.91 | RAB9A (0.39) | KMT2AMEN1RAB9ALMNAKDM4E | |
| SCHEMBL23982608 | 0.90 | RAB9A (0.38) | KMT2AMEN1RAB9ALMNAKDM4E | |
| SCHEMBL5590401 | 0.87 | GABRA1 (0.37) | KMT2AMEN1LMNAGABRA1GABRB1 | |
| SCHEMBL25940731 | 0.86 | MEN1 (0.36) | KMT2AMEN1RAB9ALMNAKDM4E | |
| SCHEMBL5588856 | 0.86 | GABRA1 (0.36) | KMT2AMEN1LMNAGABRA1GABRB1 | |
| SCHEMBL25647100 | 0.84 | LMNA (0.34) | LMNA | |
| SCHEMBL23982592 | 0.83 | KMT2A (0.35) | KMT2AMEN1RAB9ALMNAKDM4E | |
| SCHEMBL25647103 | 0.83 | LMNA (0.35) | KMT2ARAB9ALMNAGABRA1GABRB1 | |
| SCHEMBL25940738 | 0.82 | MEN1 (0.34) | KMT2AMEN1RAB9ALMNAKDM4E | |
| SCHEMBL14280811 | 0.82 | ALDH1A1 (0.39) | KMT2AMEN1LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738334-B2 | Supported catalyst systems and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11718635-B2 | Iron bis(imino) aryl catalysts and methods thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230174757-A1 | Linear Low Density Polyethylene for Film Applications | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718635-B2 | Iron bis(imino) aryl catalysts and methods thereof | IDO2, SLC40A1, IDO1 | KMT2A 1685/4885MEN1 1112/4885RAB9A 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.